Established by Malaysian Ministry of Health in 2012, Clinical Research Malaysia exists to advance global health solutions for a brighter, more hopeful future for the people by providing speedy and reliable end-to-end clinical research support for quality studies. Our innate understanding of the local clinical research landscape with the international standards of operations coupled with fundamental backing of the government ministries provide us an incomparable advantage to work with partners from the nascent stages of development to materialisation of the end product, in order to deliver better treatment and high skilled job opportunities.
Clinical Research Malaysia
Suite E-10-20, Amcorp Business Suites, Manara Melawangi,
Amcorp Trade Centre, No. 18, Jalan Persiaran Barat,
46050 Petaling Jaya, Selangor Darul Ehsan, Malaysia.
12/12/2025
Small steps lead to big futures and today marks an important milestone.
Congratulations to the third batch of the Study Coordinator Accelerated Program (SCAP) on completing their 12-week training journey! We can't wait to see the impact you’ll make in shaping Malaysia’s clinical research landscape.
A sincere thank you to our dedicated trainers and site instructors for guiding and supporting our 13 trainees. CRM wishes each of you the very best ahead!
12/12/2025
Sarawak General Hospital (SGH) has firmly established itself as one of Malaysia’s leading clinical research sites, with a strong focus on oncology and other therapeutic areas. Over the years, SGH has conducted multiple First-in-Human (FIH) studies, providing the public hospital patients with early access to innovative treatments developed globally and therapies that may otherwise take years to reach local patients. These efforts aim to provide new hope for patients with conditions that have limited treatment options, while also helping Malaysia play an important role in global medical research. Through these studies, patients benefit from cutting-edge therapies, closer monitoring, and the chance to be part of advancements that could improve care for many others in the future.
12/12/2025
Productive discussion with the ZeroRange Healthcare team recently, exploring synergies in clinical research and market access. Their comprehensive approach spanning clinical research systems, regulatory affairs, medical affairs, and patient support offers valuable solutions in navigating Malaysia's healthcare landscape. Exciting opportunities ahead in real-world evidence generation, clinical trial awareness, and bridging the gap between industry needs and investigator capabilities. Looking forward to what lies ahead!
09/12/2025
We are looking for patients with Melanoma condition. Visit the link below if you are interested to partake in our clinical trial!
CRM had a productive meeting with Mr. Arieff Aaron Abdullah, Director of the Selangor Biotechnology Coordination Office (S-BIOCO), and Ms. Faraheen, Executive at S-BIOCO.
The discussion centred around potential areas of collaboration between CRM and Invest Selangor, particularly in strengthening the biotechnology and clinical research ecosystem in Selangor.
We look forward to exploring opportunities that can support innovation, industry growth, and greater access to clinical research capabilities within the state. Thank you S-BIOCO for the engaging session.
07/12/2025
Day 1 at ESMO Asia 2025 in Singapore has been nothing short of energising for Clinical Research Malaysia!
Our team had the opportunity to reconnect with long-time partners and engage with new acquaintances who share the same commitment to advancing oncology research across the region. The congress floor was buzzing with inspiring scientific developments, reinforcing the incredible momentum in cancer innovation.
We were also thrilled to meet with industry representatives and global collaborators who are exploring new clinical trial opportunities with CRM. These discussions strengthen our mission to expand trial access, accelerate study start-up, and enable Malaysia to contribute meaningfully to the future of oncology treatments.
A great start to the conference — looking forward to more impactful connections and insights in the days ahead.
06/12/2025
What an inspiring Day at ESMO Asia 2025 as we witnessed Malaysia’s very own researchers take the podium and showcase the strength of our oncology research community on the regional stage.
A huge congratulations to A/Prof Dr Marniza Saad, Prof Dr Wan Zamaniah (UMMC) and Dr Voon PJ (Sarawak General Hospital) for their impactful presentations in the Industry Satellite Symposia and Mini Oral Presentations. Your dedication and expertise continue to elevate Malaysia’s presence in global oncology conversations.
A special mention goes to Dr. Voon, who also moderated the insightful Early Phase Development in Asia session this morning, featuring Prof Toshio Shimizu from Kansai Medical University Hospital. The room was abuzz with discussions on how investigators and institutions can embark on early-phase clinical development — a clear sign that the region is ready to push boundaries.
It is truly humbling to see Malaysia recognised as one of the emerging early-phase destinations in Asia. Just as Rome wasn’t built in a day, our early-phase ecosystem has taken years of foundational work, commitment, and collaboration to reach where it stands today.
To the young and enthusiastic investigators aspiring to be part of early-phase drug development:
Start by building your experience in Phase 2 and Phase 3 trials. Excel there. Understand the rigour, discipline, and compassion needed in clinical research. Reflect deeply on your intention to enter this field — early-phase work is demanding and requires sacrifice, but the greatest return lies in knowing that your efforts pave the way for better treatments and improved care for your patients.
Malaysia is rising, and we are proud to see our researchers leading the way.
05/12/2025
Honoured to meet with Dr. Fariz Yahya, President of the Arthritis Foundation Malaysia, to explore meaningful collaboration opportunities and future activities for the arthritis community.
Our discussion touched on shared goals in raising awareness, empowering patients, and strengthening support networks, all with the hope of improving quality of life for individuals living with arthritis.
Excited about the potential ahead and the positive impact we can create together.
05/12/2025
We are looking for patients with Crohn’s Disease condition. Visit the link below if you are interested to partake in our clinical trial!
CRM is pleased to announce the formalisation of a MoU with the Global Antibiotic Research & Development Partnership (GARDP).
This collaboration represents an important milestone in strengthening Malaysia’s contribution to global efforts addressing antimicrobial resistance (AMR). Through joint initiatives under the SECURE project, both organisations will work together to advance national research capabilities, support implementation-focused activities, and build local expertise through AMR-related training and capacity-building programmes.
This partnership underscores our shared commitment to improving patient outcomes and supporting sustainable, equitable access to essential antibiotics.
04/12/2025
Malaysia is making waves in the early phase clinical research landscape.
With streamlined approvals, accredited sites and a growing ecosystem of support, our country is emerging as a preferred destination for global early-stage trials. IQVIA’s latest white paper dives into real case milestones, start-up timelines and how Malaysia is reducing friction for sponsors and opening access for patients.
A great read for anyone in clinical research, pharma, biotech and healthcare innovation.
Join us on 8–9 Dec 2025 for the REACH Asia Forum on Community Engagement! Hear from experts and community leaders across the region on strengthening community engagement and participation in health research.
CRM is pleased to share that our Chief Executive Officer, Dr Akhmal Yusof, will be speaking at the forum, sharing insights on Malaysia’s clinical research landscape and the importance of meaningful community engagement.
Register at ad-id.co/reach2025
Address
D-26-06, Menara Suezcap 1, KL Gateway, No. 2, Jalan Kerinchi, Gerbang Kerinchi Lestari Kuala Lumpur 59200
Be the first to know and let us send you an email when Clinical Research Malaysia posts news and promotions. Your email address will not be used for any other purpose, and you can unsubscribe at any time.
Clinical Research Malaysia (CRM) was established by the Malaysian Ministry of Health in 2012 with its sole existence anchored on advancing global health solutions for a brighter, more hopeful future for the people. To that end, we provide speedy and reliable end-to-end clinical research support for quality studies to our partners. In our pursuit of excellence, we continuously strive to improve on the delivery of our expertise to meet our partners’ needs by tapping into the breadth and depth of our organisation’s clinical research prowess. As these studies unfold, we work together with our partners to create an impetus in delivering better treatment to patients, while at the same time creating high-skilled job opportunities.
The strength of our operation lies in of our innate understanding of the local clinical research landscape and implementation of international standards.This, when considered in parallel to the fundamental backing of the government ministries, provides us with an incomparable advantage, as we work hand-in-hand with our partners from the nascent stages of development to materialisation of the end product.
In the journey towards a brighter and better future, we facilitate the entry of industry-sponsored research into Malaysia, working closely with the government and relevant authorities to ensure that all regulations and best practices are met.
Having cumulated a wealth of experience in the clinical research industry, we recognise that pivotal factors such as financial prudence, speed in delivery quality end product and reliability form the core of our integrity among our partners. As such, we ensure core values of transparency, honesty, accountability and trustworthiness resonate throughout CRM. These values make up our DNA and are evident in our practices regardless of whether we are fronting patients, partners or patrons, or in our individual workplaces – the ethical conduct form the core of our culture. These values are also cascaded to our principal investigators and study coordinators, who act as the catalysts of the clinical research process.
In CRM, we credit the outstanding performance to the team that we have anchored within our organisation. Their endless pursuit of innovation and continuous improvement have propelled CRM forward to optimise the opportunities that come our way. At a macroscopic level, Malaysia inherits a wealth of patient pool that accommodates a diverse range of clinical researches requirement, competent principal investigators and strength to assist partners in progressing through clinical trials that produce quality results with minimal cost and speediest timeline.
As CRM vouches for an aspiring future in the medical industry, we have implemented mechanisms to expand hospital capacity for clinical trials and tests. This is possible by tapping into our vast talent pool consisting of principal investigators and medical assistants.
-------------------------------------------------------------------------------------------------
Clinical Research Malaysia
Suite E-10-20, Amcorp Business Suites, Manara Melawangi,
Amcorp Trade Centre, No. 18, Jalan Persiaran Barat,
46050 Petaling Jaya, Selangor Darul Ehsan, Malaysia.
t: +603 7960 5153 | f: +603 7932 1940 | e: contact@clinicalresearch.my
